Drug Approval | March 19, 2024
Sun Pharmaceuticals receives approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
BHL will undertake the development and supply of these molecules
Sustainability is integral to Biocon's business purpose
iSolveSM information on demand is the result of our focus on customer relationship
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
